KALA BIO ( (KALA) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kala Bio, Inc. has filed a Form 12b-25 to notify investors that its Annual Report on Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025 will be delayed.
The company cites heavy director and officer turnover since November 2025 and a major shift in business strategy as key reasons, noting it needs more time to gather documentation and finalize its financial statements and disclosures.
Despite the delay, Kala Bio expects to submit the Form 10-K (Yearly Report) within the standard grace period, no later than the fifteenth calendar day after the original filing deadline.
This timeline follows the relief provided under SEC rules for late filings when completing the report on time would require unreasonable effort or expense.
Operationally, the company is signaling a significant change in results, with an anticipated 2025 net loss of about $27.3 million versus a $38.5 million net loss in 2024.
The narrower loss is mainly tied to gains from fair value remeasurement of contingent consideration, debt extinguishment, and settlements, along with lower R&D after ceasing development of its KPI-012 program and MSC-S platform.
These positives are partly offset by roughly $5.6 million higher general and administrative costs, largely driven by professional fees and employee-related expenses tied to the strategic wind-down of those programs.
Kala Bio stresses that these figures are preliminary and subject to completion of normal year-end closing procedures and the audit process, and actual results may materially differ from current expectations.
The company also reminds investors that statements about its expected financial results, timing of the Form 10-K (Yearly Report) filing, and completion of required work are forward-looking and exposed to various risks and uncertainties.
It acknowledges potential delays, the provisional nature of the numbers, and broader risk factors previously disclosed in its SEC filings.
Kala Bio indicates it has one outstanding periodic filing besides the Form 10-K (Yearly Report), a Form 8-K relating to a promissory note from February 9, 2026, but reiterates its intent to remain in compliance with reporting obligations.
The Form 12b-25 notification is signed on behalf of the company by Chief Executive Officer Avi Minkowitz on March 31, 2026, underscoring executive-level oversight of the delayed filing process.
The most recent analyst rating on (KALA) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
The score is driven primarily by very weak financial performance (near-zero revenue, large ongoing losses, negative equity, and substantial cash burn). Technicals are also negative with the stock below key moving averages and a negative MACD. Corporate events are mixed—debt overhang reduction helps, but Nasdaq compliance issues materially elevate risk; valuation metrics provide limited support given negative earnings and no dividend.
To see Spark’s full report on KALA stock, click here.
More about KALA BIO
Average Trading Volume: 7,136,464
Technical Sentiment Signal: Sell
Current Market Cap: $155.8M
For a thorough assessment of KALA stock, go to TipRanks’ Stock Analysis page.